Globus Medical vs ICU Medical
GMED and ICUI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GMED and ICUI compare
Globus Medical is the larger company, worth 2.6 times as much as ICU Medical ($10.5B against $4.1B).
On earnings, Globus Medical is cheaper: it trades at 20.0× trailing earnings, against 136× for ICU Medical.
Globus Medical grew revenue faster over the last twelve months (19.7% versus −9.0% for ICU Medical).
Globus Medical keeps more of each dollar of sales as profit, with a net margin of 17.0% compared with 1.4% at ICU Medical.
Globus Medical scores higher on the StockData Score (23 against 8 for ICU Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GMED | ICUI |
|---|---|---|
| Size and price | ||
| Market cap | $10.5B | $4.1B |
| Share price | $78.05 | $163.78 |
| Change, 1 year | 27.0% | 39.2% |
| Change, 5 years | −0.46% | −32.1% |
| Beta (5Y) | 0.95 | 1.01 |
| Employees | 6,000 | 13K |
| StockData Score | ||
| Total score | 23 (better) | 8 |
| Valuation score | 6 (better) | 2 |
| Growth score | 6 (better) | 2 |
| Performance score | 5 (better) | 3 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 20.0× (better) | 136× |
| P/S | 3.3× | 1.9× (better) |
| P/B | 2.2× | 1.9× (better) |
| EV/EBITDA | 10.8× (better) | 18.4× |
| P/FCF | 13.9× (better) | 26.8× |
| PEG | 0.70 | – |
| FCF yield | 7.2% (better) | 3.7% |
| Fair value | $126.34 | $137.43 |
| Margin of safety | 38.2% (better) | −19.2% |
| Growth | ||
| Revenue growth (TTM) | 19.7% (better) | −9.0% |
| Revenue growth, 5Y average | 30.1% (better) | 11.9% |
| Net income growth (TTM) | 50.1% | – |
| EPS growth (TTM) | 50.4% | – |
| EPS growth, 5Y average | 31.2% (better) | −62.5% |
| Profitability | ||
| Gross margin | 68.5% (better) | 39.1% |
| Operating margin | 20.3% (better) | 3.3% |
| Net margin | 17.0% (better) | 1.4% |
| FCF margin | 24.0% (better) | 7.1% |
| Return on equity | 11.8% (better) | 1.4% |
| Return on invested capital | 12.6% (better) | 2.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.57 (better) |
| Net debt / EBITDA | – | 3.41 |
| Interest coverage | – | 0.9× |
| Current ratio | 4.62 (better) | 2.43 |
| Altman Z-score | 10.46 (better) | 2.43 |
| Piotroski F-score | 9 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | 2.1% | – |
| Shareholder yield | 2.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 88.9% | 104% |
| Held by insiders | 17.8% | 1.8% |
| Insider net buying, 12 months | −$17.5M | −$8.3M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.6% | 6.2% |
Go deeper
- GMED stock overview
- GMED income statement
- GMED valuation and score
- ICUI stock overview
- ICUI income statement
- ICUI valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.